1. FDA Drug Safety Communication issued 01-10-2013. https://wayback.archive-it.org/7993/20170404172106/https://www.fda.gov/Drugs/DrugSafety/ucm334033.htm [accessed September 2019].
2. FDA Drug Safety Communication issues 05-14/2013. https://wayback.archive-it.org/7993/20170406043943/https://www.fda.gov/Drugs/DrugSafety/ucm352085.htm [accessed September 2019].
3. Drug Approval Package: Ambien (zolpidem tartrate) NDA 19908. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019908_S000_AmbienTOC.cfm [accessed September 2019].
4. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications;Salva;Clin Pharmacokinet,1995
5. Press release: FDA approves Intermezzo. https://www.drugs.com/newdrugs/fda-approves-intermesso-middle-night-waking-followed-difficulty-returning-sleep-2962.htm [accessed September 2019].